Interrelations Between Cellular DNA Content, S-Phase Fraction, Hormone Receptor Status and Age in Primary Breast Cancer A Series of 1 342 Consecutively Detected Tumors

References

• Clark G M, Dressier L G, Owens M A, Pounds G, Oldaker T, McGuire W L. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Eng Med 1989; 320: 627–33
   PubMed Web of Science ®Google Scholar
• Crowe J P, Hubay C A, Pearson O H, et al. Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Treat 1982; 2: 171–6
   PubMedGoogle Scholar
• Godolphin W, Elwood J M, Spinelli J J. Estrogen receptor quantitation and staging as complementary prognostic indicators in breast cancer: a study of 583 patients. Int J Cancer 1981; 28: 677–83
   PubMed Web of Science ®Google Scholar
• Kallioniemi O-P, Blanco G, Alavaikko M, Hietanen T, Lauslahti K, Koivula T. Tumour DNA ploidy as an independent prognostic factor in breast cancer. Br J Cancer 1987; 56: 637–42
   PubMed Web of Science ®Google Scholar
• Klintenberg C, Stål O, Nordenskjöld B, Wallgren A, Aryidsson S, Skoog L. Proliferative index, cytosol estrogen receptor and axillary node status as prognostic predictors in human mammary carcinoma. Breast Cancer Res Treat 1986; 7: 99–106, (Suppl)
   Web of Science ®Google Scholar
• Raemaekers J MM, Bex L VAM, Koenders A JM, et al. Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up. Breast Cancer Res Treat 1985; 6: 123–30
   PubMed Web of Science ®Google Scholar
• von Rosen A, Rutquist L E, Carstensen J, Fallenius A, Skoog L. Prognostic value of nuclear DNA content in breast cancer in relation to tumor size, nodal status, and estrogen receptor content. Breast Cancer Res Treat 1989; 13: 23–32
   PubMed Web of Science ®Google Scholar
• Shek L L, Godolphin W. Survival with breast cancer: the importance of estrogen receptor quantity. Eur J Cancer Clin Oncol 1989; 25: 243–50
   PubMedGoogle Scholar
• Sigurdsson H, Baldetorp B, Borg Å, et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990; 322: 1045–53
   PubMed Web of Science ®Google Scholar
• Skoog L, Humla S, Axelsson M, et al. Estrogen receptor levels and survival of breast cancer patients. A study on patients participating in randomized trials of adjuvant therapy. Acta Oncol 1987; 26: 95–100
   PubMed Web of Science ®Google Scholar
• Spyratos F, Hacene K, Tubiana-Hulin M, Pallud C, Brunet M. Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. A sequential multivariate analysis of 1 261 patients. Eur J Cancer Clin Oncol 1989; 25: 1233–40
   PubMedGoogle Scholar
• Stål O, Wingren S, Carstensen J, et al. Prognostic value of DNA ploidy and S-phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer. Eur J Cancer Clin Oncol 1989; 25: 301–9
   PubMedGoogle Scholar
• Stål O, Hatschek T, Carstensen J, Nordenskjöld B. DNA analysis in the management of breast cancer. Diagn Oncol 1991; 1: 140–54
   Google Scholar
• Thorpe S M, Rose C, Rasmussen B B, Mouridsen H T, Bayer T, Keiding N. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res 1987; 47: 6126–33
   PubMed Web of Science ®Google Scholar
• Toikkanen S, Joensuu H, Klemi P. The prognostic significance of nuclear DNA content in invasive breast cancer — a study with long-term follow-up. Br J Cancer 1989; 60: 693–700
   PubMed Web of Science ®Google Scholar
• Vollenweider-Zeragui L, Barrelet L, Wong Y, Lemarchand-B T, Gomez F. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients. Cancer 1986; 57: 1171–80
   PubMed Web of Science ®Google Scholar
• Dressler L G, Seamer L C, Owens M A, Clark G M, McGuire W L. DNA flow cytometry and prognostic factors in 1 331 frozen breast cancer specimens. Cancer 1988; 61: 420–7
   PubMed Web of Science ®Google Scholar
• Feichter G E, Mueller A, Kaufmann M, et al. Correlation of DNA flow cytometric results and other prognostic factors in primary breast cancer. Int J Cancer 1988; 41: 823–8
   PubMed Web of Science ®Google Scholar
• Kute T E, Muss H B, Hopkins M, Marshall R, Case D, Kammire L. Relationship of flow cytometry results to clinical and steroid receptor status in human breast cancer. Breast Cancer Res Treat 1985; 6: 113–21
   PubMed Web of Science ®Google Scholar
• Hatschek T, Fagerberg G, Stal O, Sullivan S, Carstensen J, Grontoft O. Cytometric characterization and clinical course of breast cancer diagnosed in a population based screening program. Cancer 1989; 64: 1074–81
   PubMed Web of Science ®Google Scholar
• Meyer J S, Prey M U, Babcock D S, McDivitt R W. Breast carcinoma cell kinetics, morphology, stage, and host characteristics. Lab Invest 1986; 54: 41–51
   PubMed Web of Science ®Google Scholar
• Hedley D W, Rugg C A, Gelber R D. Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res 1987; 47: 4729–35
   PubMed Web of Science ®Google Scholar
• Dowle C S, Owainati A, Robins A, et al. Prognostic significance of the DNA content of human breast cancer. Br J Surg 1987; 74: 133–6
   PubMed Web of Science ®Google Scholar
• McDivitt R W, Stone K R, Craig R B, Palmer J O, Meyer J S, Bauer W C. A proposed classification of breast cancer based on kinetic information. Cancer 1986; 57: 269–76
   PubMed Web of Science ®Google Scholar
• O'Reilly S M, Camplejohn R S, Barnes D M, et al. DNA index, S-phase fraction, histological grade and prognosis in breast cancer. Br J Cancer 1990; 61: 671–4
   PubMed Web of Science ®Google Scholar
• Clark G M, Osborne C K, McGuire W L. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 1984; 2: 1102–9
   PubMed Web of Science ®Google Scholar
• Fernö M, Borg A, Johansson U, et al. Estrogen and progesterone receptor analyses in more than 4 000 human breast cancer samples. A study with special reference to age at diagnosis and stability of analysis. Acta Oncol 1990; 29: 129–35
   PubMed Web of Science ®Google Scholar
• Thorpe S M. Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance. Acta Oncol 1988; 27: 1–19
   PubMed Web of Science ®Google Scholar
• Wilking N, Rutqvist L E, Nordenskjöld B, Skoog L. Steroid receptor levels in breast cancer. Relationships with age and menopausal status. Acta Oncol 1989; 28: 807–10
   PubMed Web of Science ®Google Scholar
• Vindelöv L L, Christensen I J, Nissen N I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983; 3: 323–7
   PubMedGoogle Scholar
• Armitage P, Berry G. Statistical methods in medical research. Blackwell Scientific Publications, Oxford 1987
   Google Scholar
• Degeshein G A, Bloom N, Tobin E. The value of progesterone receptor assays in the management of advanced breast cancer. Cancer 1976; 46: 2789–93
   Google Scholar
• Thorpe S M. Immunological quantitation of nuclear receptors in human breast cancer: relation to cytosolic estrogen and progesterone receptors. Cancer Res 1987; 47: 1830–5
   PubMed Web of Science ®Google Scholar
• Fernö M, Borg Å, Sellberg G. Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing. Acta Radiol Oncol 1986; 25: 171–5
   PubMed Web of Science ®Google Scholar
• Coulson P B, Thronthwaite J T, Woolley T W, Sugarbaker E V, Seckinger D. Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival. Cancer Res 1984; 44: 4187–96
   PubMed Web of Science ®Google Scholar
• Vindelöv L L, Christensen I J. A review of techniques and results obtained in one laboratory by an integrated system of methods designed for routine clinical flow cytometric DNA analysis. Cytometry 1990; 11: 753–70
   PubMedGoogle Scholar
• van Netten J P, Algard F T, Coy P, et al. Heterogeneous estrogen receptor levels detected via multipole microsamples from individual breast cancers. Cancer 1985; 56: 2019–24
   PubMed Web of Science ®Google Scholar
• Cohen O, Brugal G, Seigneurin D, Demongeot J. Image cytometry of estrogen receptors in breast carcinomas. Cytometry 1988; 9: 579–87
   PubMedGoogle Scholar
• Cudahy T J, Boeryd B R, Frånlund B K, Nordenskjöld B. A comparison of three different methods for the determination of estrogen receptors in human breast cancer. Am J Clin Pathol 1988; 90: 583–90
   PubMed Web of Science ®Google Scholar
• Osborne C K. Heterogeneity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol 1985; 12: 317–26
   PubMed Web of Science ®Google Scholar
• Lippman M E, Dickson R B, Bates S, et al. Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat 1986; 7: 59–70
   PubMed Web of Science ®Google Scholar
• Dickson R B, Lippman M E. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endoc Rev 1987; 8: 29–43
   PubMed Web of Science ®Google Scholar
• Borg Å, Linell F, Idvall I, et al. HER2 neu amplification and comedo type breast cancer. Lancet 1989; 1: 1268
   PubMedGoogle Scholar
• Sainsbury J RC, Malcolm A, Appleton D, Farndon J R, Harris A L. Presence of epidermal growth factor receptors as an indicator of poor prognosis in patients with breast cancer. J Clin pathol 1985; 38: 1225–8
   PubMed Web of Science ®Google Scholar
• Spyratos F, Delaure J-C, Andieu C, et al. Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res Treat 1990; 17: 83–9
   PubMed Web of Science ®Google Scholar
• Skoog L, Macias A, Azavedo E, Lombardero J, Klintenberg C. Receptors for EGF and oestradiol and thymidinekinase activity in different histological subgroups of human mammary carcinomas. Br J Cancer 1986; 54: 271–6
   PubMed Web of Science ®Google Scholar
• Nicholson S, Harris A L, Farndon J R. Role of receptors in the management of patients with breast cancer. Diagn Oncol 1991; 1: 43–52
   Web of Science ®Google Scholar
• von Rosen A, Fallenius A, Sundelin B, Auer G. Nuclear DNA content in mammary carcinomas in women aged 35 or younger. Am J Clin Oncol 1986; 9: 382–6
   PubMed Web of Science ®Google Scholar
• Ewers S B, Långström E, Baldetorp B, Killander D. Flow-cytometric DNA analysis in primary breast carcinomas and clinicopathological correlations. Cytometry 1984; 5: 408–19
   PubMedGoogle Scholar
• Olsson H. Reproductive events, occurring in adolescence at the time of development of reporductive organs and at the time of tumour initiation, have a bearing on growth characteristics and reproductive hormone regulation in normal and tumour tissue investigated decades later—A hypothesis. Med Hypotheses 1989; 28: 93–7
   PubMed Web of Science ®Google Scholar
• Simpson H W, Pauson A W, Griffiths K, Candlish W, McArdle C S, Small R G. Genesis of breast cancer is in the premenopause. Lancet 1988; 2: 74–6
   PubMedGoogle Scholar